Welcome to the e-CCO Library!

P426: Meta-analysis of endorectal advancement flap vs. ligation of the intersphincteric fistula tract for Crohn’s and cryptoglandular high perianal fistulas
Year: 2018
Source: ECCO '18 Vienna
Authors:

M.E. Stellingwerf*, E.M. van Praag, W.A. Bemelman, C.J. Buskens

Created: Thursday, 21 February 2019, 9:14 AM
P426: Post-induction adalimumab drug levels predict clinical and laboratory remission at week 24 in patients with Crohn’s disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

E. Zittan*1, 2, O. B. Kelly1, B. Kabakchiev1, G. C. Nguyen1, K. Croitoru1, A. H. Steinhart1, M. S. Silverberg1

Created: Friday, 22 February 2019, 9:49 AM
P426: Sex and sexuality in IBD - the pediatric gastroenterologists' point of view
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Anafy, A.(1,2);Cohen, S.(1,2);Matar, M.(3);Shouval, D.S.(2,3);Shamir, R.(2,3);Weintraub, Y.(2,3)*;
Created: Friday, 14 July 2023, 11:05 AM
P426: Supra-therapeutic infliximab levels are not associated with a higher risk of infection in IBD patients
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Greener T.*1, Kabakchiev B.2, Silverberg M.3

Created: Wednesday, 20 February 2019, 10:36 AM
P427 A hybrid approach of handling missing data in inflammatory bowel disease (IBD) trials: results from VISIBLE 1 and VARSITY
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Chen1, S. Hunter2, K. Kisfalvi3, R.A. Lirio4

Created: Thursday, 30 January 2020, 10:12 AM
P427: Development of an index that predicts escalation of therapy at an outpatient appointment in patients with known ulcerative colitis (UC)
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Walsh1*, P. Seeva1, C. Hinds2, V. Sexton3, O. Brain1, S. Keshav1, H. Uhlig1, J. Geddes3, G. Goodwin3, M. Peters4, G. Collins5, S. Travis1

Created: Thursday, 21 February 2019, 9:14 AM
P427: Efficacy and safety of vedolizumab and adalimumab in Asian adults with moderately to severely active ulcerative colitis: Post-hoc analysis of the VARSITY trial
Year: 2021
Source: ECCO'21 Virtual
Authors: Kim, J.S.(1);Leung, W.K.(2);Wu, D.C.(3);Lindner, D.(4);Fadeeva, O.(5);Demuth, D.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P427: Exploring phenotype and treatment of inflammatory bowel disease in the elderly
Year: 2022
Source: ECCO'22
Authors: Gaglani, R.(1);Balarajah, S.(1);Williams, H.(1);Hicks, L.(1);
Created: Friday, 11 February 2022, 3:52 PM
P427: Impact of curcuma longa on clinical activity and inflammatory markers in patients with active ulcerative colitis: a double-blind randomised placebo-controlled trial
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Kumar1, U. Dutta1, J. Shah*1, P. Singh1, C. Vaishnavi1, K. K. Prasad1, K. Singh1

Created: Friday, 22 February 2019, 9:41 AM
P427: Neutrophil-to-lymphocyte ration in ulcerative colitis predicts sustained response to infliximab
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Nishida Y.*1, Hosomi S.1, Watanabe K.2, Yukawa T.1, Otani K.1, Nagami Y.1, Tanaka F.1, Taira K.1, Kamata N.1, Shiba M.1, Yamagami H.1, Tanigawa T.1, Watanabe T.1, Tominaga K.1, Fujiwara Y.1

Created: Wednesday, 20 February 2019, 10:36 AM
P427: One Year Follow up of Three Phase IB/IIA Clinical Trials of Ex Vivo Expanded Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulizing Crohn's Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lightner, A.(1)*;Otero Pineiro MD , A.(2);Reese, J.(3);Ream, J.(4);Nachand, D.(4);Obi, M.(2);Adams, A.(2);VanDenBossche , A.(2);Dadgar, N.(2);Hull, T.(2);
Created: Friday, 14 July 2023, 11:05 AM
P427: The real-life experience of vedolizumab efficacy and safety in Crohn’s disease: a prospective observational multicentre cohort study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Amiot*1, J. C. Grimaud2, X. Treton3, J. Filippi4, B. Pariente5, L. Peyrin-Biroulet6, A. Noureille7, A. Buisson8, F. Carbonnel9, A. Bourrier10, S. Nancey11, X. Roblin12, P. Marteau13, R. Altwegg14, J. Moreau15, A. Aubourg16, G. Savoye17, A. L. Pelletier18, M. Fumery19, B. Bonaz20, Y. Bouhnik3

Created: Friday, 22 February 2019, 9:49 AM
P428 Oral mesalamine use in Crohn’s disease after implementation of the American College of Gastroenterology guidelines: a TARGET-IBD cohort study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. Gupta1, B.E. Sands2, M. Regueiro3, M. Dubinsky4, D. Rubin5, J. Hanson6, F. Aberra7, M. Weiss8, S. Watkins9, D. Gazis10, M. Long11

Created: Thursday, 30 January 2020, 10:12 AM
P428: A Phase IB/IIA study of remestemcel-L, an allogeneic bone marrow derived mesenchymal stem cell product, for the treatment of medically refractory Crohn’s colitis: A preliminary analysis
Year: 2022
Source: ECCO'22
Authors: Lightner, A.(1);Ream, J.(2);Nachand, D.(2);Fulmer, C.(3);Regueiro, M.(4);Steele, S.(5);
Created: Friday, 11 February 2022, 3:52 PM
P428: Early and Late Fecal Calprotectin Remission - Analysis of a proactive Therapeutic Drug Monitoring Treatment Protocol
Year: 2021
Source: ECCO'21 Virtual
Authors: Pedro, J.(1);Rodrigues, I.(1);Damião, F.(1);Fernandes, S.(1);Gonçalves, A.R.(1);Bernardo, S.(1);Baldaia, C.(1);Valente, A.(1);Moura Santos, P.(1);Correia, L.(1);Tato Marinho, R.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P428: Long-term outcomes of endoscopic ballon dilation for small-bowl strictures using double balloon enteroscopy in patients with Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Takeda*1, F. Hirai1, N. Takatsu1, M. Kishi2, T. Beppu2, K. Yao3, T. Ueki2

Created: Friday, 22 February 2019, 9:41 AM
P428: Optimizing thiopurines in Crohn's disease: low dose and low 6-TGN level are effective for maintenance of remission in Asian population
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Mao R.1, Guo J.1, Ben Horin S.1,2, Chen M.*3

Created: Wednesday, 20 February 2019, 10:36 AM
P428: Pharmacist led clinic in Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kwok, J.(1)*;Smith, J.(2);Gashau, W.(2);Shuttleworth, E.(2);
Created: Friday, 14 July 2023, 11:05 AM
P428: Pharmacist-led proactive therapeutic drug monitoring with infliximab (PROXIMO): Utility of and cost-saving associated with the use of a rapid assay for assessing drug level
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Rentsch1*, M. Sparrow2,3, M. Ward2,3, K. Taylor2,3, A. Friedman2,4, R. Luber2,3, H. Su2, R. Hopkins1, B. Head-on2, M. Dooley2,3, P. Gibson2,4

Created: Thursday, 21 February 2019, 9:14 AM
P428: Tofacitinib pharmacokinetics and durability of drug exposure in moderate-to-severe Crohn’s disease patients in Phase 2 induction and maintenance studies
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Mukherjee1, C. Deng2, R. Xie2, S.W. Martin3, G. Chan4, M. Moscariello4, W. Niezychowski4, E. Maller*4

Created: Friday, 22 February 2019, 9:49 AM